Patent application number | Description | Published |
20080300170 | Compositions and methods for diagnosis and treatment for type 2 diabetes - The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes. | 12-04-2008 |
20090203602 | Compositions and methods for diagnosis and treatment of type 2 diabetes - The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes. | 08-13-2009 |
20090285843 | EPITOPE SEQUENCES - Disclosed herein are polypeptides, including epitopes, clusters, and antigens. Also disclosed are compositions that include said polypeptides and methods for their use. | 11-19-2009 |
20100197596 | Compositions and methods for diagnosis and treatment of type 2 diabetes - The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes. | 08-05-2010 |
20100267052 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE 2 DIABETES - The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes. | 10-21-2010 |
20100303842 | PEPTIDE ANALOGUES - Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed. | 12-02-2010 |
20110177047 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS - The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 07-21-2011 |
20110301327 | EPITOPE ANALOGS - Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed. | 12-08-2011 |
20120148613 | MULTIVALENT ENTRAIN-AND-AMPLIFY IMMUNOTHERAPEUTICS FOR CARCINOMA - The present invention provides a method of treating a cell proliferative disease such as cancer by providing to a subject in need thereof an immunogenic composition comprising plasmid and peptide(s) or analogues thereof. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response. | 06-14-2012 |
20130017213 | PEPTIDE ANALOGUES - Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed. | 01-17-2013 |
20130058965 | INJECTABLE FORMULATIONS FOR PARENTERAL ADMINISTRATION - Disclosed herein are uses, methods, and processes for preparing or manufacturing a lyophilized cake that comprises a water-insoluble agent, wherein the cake is capable of being disintegrated in a parenterally acceptable solvent to form a syringeable liquid suspension of fine particles of the water-insoluble active agent that is suitable for pharmaceutical uses. Lyophilized cakes prepared according to the methods disclosed herein and kits containing such lyophilized cakes are also disclosed. Further disclosed herein are methods and processes for preparing a syringeable liquid suspension of fine particles of the water-insoluble active agent that is suitable for pharmaceutical uses. | 03-07-2013 |
20130059799 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME - The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant. | 03-07-2013 |
20130195901 | SSX-2 PEPTIDE ANALOGS - Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed. | 08-01-2013 |
20140044689 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS - The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 02-13-2014 |
20150065437 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME - The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant. | 03-05-2015 |
20160058825 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS - The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pi gmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 03-03-2016 |
Patent application number | Description | Published |
20120195213 | Method and Equipment for Reporting Channel State Information Aperiodically - The disclosure discloses a method and device for reporting channel state information aperiodically. Wherein the method comprises: collecting the channel state information reported by the UE through the configured receiving window; determining the change speed degree of the channel state of the UE according to the criterion for determining a change speed of the channel state information; deciding whether the UE needs to perform aperiodic reporting according to the mapping relationship between the change speed degree of the channel state information and a reporting period adjusting value, and determining timing for the aperiodic reporting if needed. By the method of the disclosure, on one hand, the base station sufficiently obtains the channel state information reported by the UE, which benefits for more suitable scheduling and resource allocating for the UE; on the other hand, PUSCH resources can be used more rationally. | 08-02-2012 |
20120207238 | METHOD AND APPARATUS FOR PROCESSING PRECODER - The present invention provides a method and an apparatus for processing a precoder. The method comprises: step A: a base station determining whether the number of received effective precoders reported by a certain UE is greater than or equal to a threshold a, if so, executing step B, otherwise, executing step D; step B: the base station determining whether each received effective precoder is according to the same number of layers, if so, executing step C, otherwise, executing step D; step C: the base station determining whether a variation speed of each effective precoder is fast, if so, applying a transmit diversity transmission mode to the UE, otherwise, applying a MIMO transmission mode to the UE; and step D: applying the MIMO transmission mode to the UE. Therefore, the present invention can reasonably predict the transmission mode and the precoder that should be employed in the transmission mode at current time for a certain UE. | 08-16-2012 |
20150117278 | LTE-based method, system, and device for ultra-distance coverage communication - An LTE-based method, system, and device for ultra-distance coverage communication. The method comprises: increasing an uplink feedback subframe interval at a terminal side and an uplink feedback subframe interval at a base station side; after receiving uplink scheduling information sent by the base station side, the terminal side sending data over a subframe whose subframe interface is the increased uplink feedback subframe interval at the terminal side; and the terminal side receiving data verification information that is delivered by the base station side over a subframe whose subframe interval is the increased uplink feedback subframe interval at the base station side. | 04-30-2015 |
20150203538 | COMPOSITIONS AND METHODS OF USING ISLET NEOGENESIS PEPTIDES AND ANALOGS THEREOF - The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for trans plantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation. | 07-23-2015 |
20160039877 | COMPOSITIONS AND METHODS OF USING ISLET NEOGENESIS PEPTIDES AND ANALOGS THEREOF - The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation. | 02-11-2016 |